GREENLAND MINES LTD Noninterest Expense Investment Advisory Fees
GREENLAND MINES LTD (GRML) had Noninterest Expense Investment Advisory Fees of $90.00 million as of 2024-06-21, per its 10-Q filed 2025-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:NoninterestExpenseInvestmentAdvisoryFees · last filed 2025-05-15
- 2024-06-21: Noninterest Expense Investment Advisory Fees $90.00M.
| Period end | Noninterest Expense Investment Advisory Fees |
|---|---|
| 2024-06-21 | $90.00M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |